Mitochondrial 3243A > G mutation confers pro-atherogenic and pro-inflammatory properties in MELAS iPS derived...

Area of Science:

• Mitochondrial genetics
• Vascular biology
• Pathophysiology of rare diseases

Background:

• Mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS) syndrome is a mitochondrial disorder often caused by the m.3243A>G mutation in the MT-TL1 gene.
• Clinical manifestations include cerebral infarcts, altered vasculature, and stroke-like episodes, but the underlying mechanisms remain unclear.

Purpose of the Study:

• To investigate the role of the m.3243A>G mutation in endothelial cell dysfunction and atherosclerosis development in MELAS syndrome.
• To explore the potential of antioxidant treatment in reversing MELAS-associated endothelial phenotypes.

Main Methods:

• Analysis of endothelial cells (ECs) from MELAS patients carrying the m.3243A>G mutation.
• Assessment of reactive oxygen species (ROS) levels, oxidized low-density lipoprotein (Ox-LDL) uptake, and VCAM-1 expression in MELAS ECs.
• Monocyte adhesion assays comparing MELAS ECs to isogenic controls.
• Evaluation of the effects of antioxidant treatment on MELAS EC phenotypes.

Main Results:

• MELAS ECs exhibited endothelial dysfunction, characterized by high ROS and Ox-LDL levels, and elevated VCAM-1 expression.
• Diseased ECs demonstrated pro-atherogenic and pro-inflammatory properties, with increased monocyte adhesion compared to controls.
• Antioxidant treatment effectively reversed the observed disease phenotypes in MELAS endothelial cells.

Conclusions:

• The m.3243A>G mutation contributes to MELAS pathogenesis through endothelial dysfunction and promotion of an atherosclerosis-like state.
• Reducing ROS levels is a critical therapeutic strategy for managing MELAS syndrome and its vascular complications.